MetaCap

Genelux (GNLX) vs OnKure Therapeutics (OKUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Genelux (GNLX) over the past year, gaining 4.7% versus a loss of 56.3%. OnKure Therapeutics is the larger company by market cap ($111.2 million vs $103.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GNLX-56.25%OKUR+4.65%
+113%+20%-72%
Nov 21, 20251 yearNov 20, 2026
GNLX-63.89%OKUR-89.93%
+511%+195%-122%
Jan 23, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GNLX versus OKUR key metrics
MetricGNLXOKUR
Share price$2.17$2.70
Market cap$103.36M$111.21M
1-day change-4.82%-2.17%
YTD return-50.23%-6.90%
1-year return-56.25%+4.65%
5-year return—-96.16%
EPS (TTM)$-0.88$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.00K—
Revenue growth (YoY)0.00%—
Net income (latest FY)$-32.15M$-59.52M
Operating margin-415175.00%—
Net margin-401812.50%—
52-week high$5.89$5.38
52-week low$1.77$2.01
Distance from 52-week high-63.16%-49.81%
Analyst consensusstrong_buynone
Avg. price target upside+767.74%+464.81%
Average volume333.31K335.78K
Shares outstanding47.63M40.50M
Employees2545
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKUR has outperformed GNLX by 60.9 percentage points over the past year.

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

GNLX vs OKUR FAQ

Which is bigger, Genelux or OnKure Therapeutics?

OnKure Therapeutics (OKUR) is larger, with a market capitalization of $111.21M compared with $103.36M for Genelux (GNLX).

Which stock has performed better over the past year, GNLX or OKUR?

OKUR returned +4.65% over the past 12 months, compared with -56.25% for GNLX (price return, excluding dividends). Past performance does not predict future results.

Are Genelux and OnKure Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons